Clinical Trials

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03333343 2026-01-16

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

105 enrolled

EGFR-mutant Non-small Cell Lung Cancer

NCT04452877 2026-01-13

A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC

Phase 2 Completed

40 enrolled 17 charts

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04892017 2025-10-10

A Phase 1/2 Study of Inlexisertib (DCC-3116) in Patients With RAS/MAPK Pathway Mutant Solid Tumors

144 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03299088 2025-05-21

Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations

15 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung

NCT02974725 2025-04-13

A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

Phase 1/2 Not yet recruiting

241 enrolled

DermatologicThoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma

NCT05275374 2025-04-10

ENHANCE

221 enrolled

DermatologicGastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms

NCT06532149 2024-08-09

EROS

Recruiting

80 enrolled

OtherThoracic

Carcinoma, Non-Small-Cell Lung, Eunuchism, Erectile Dysfunction, Sexual Dysfunction, Physiological

NCT05435846 2024-06-11

Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation

3 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04967079 2024-04-23

Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients

33 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03076164 2024-04-02

A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib

Phase 1/2 Completed

24 enrolled 8 charts

Adenocarcinoma of Lung, Lung Neoplasms

NCT03516214 2024-02-15

EATON

18 enrolled

Bronchial Neoplasms

NCT05988697 2023-10-12

Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib

Not yet recruiting

36 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01912625 2023-05-06

Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

16 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03087448 2022-12-27

Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

9 enrolled

177 enrolled 19 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT01336634 2022-04-04

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02900664 2022-03-29

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

BreastGastrointestinalThoracic

283 enrolled

Adenocarcinoma of Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Ductal, Triple Negative Breast Neoplasms

NCT03232892 2019-12-03

Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer

Phase 2 Terminated

1 enrolled 7 charts

Carcinoma, Non-Small-Cell Lung

NCT01938443 2019-07-12

A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors

Other solid neoplasmThoracic

34 enrolled

Mesothelioma, Neoplasms

NCT02258607 2019-02-01

Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase

21 enrolled

Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer

NCT02580708 2018-10-02

Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer

Phase 1/2 Terminated

7 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02672358 2018-08-10

Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT03266159 2017-12-08

A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors

Phase 2 Withdrawn

Small Cell Lung Carcinoma

NCT02538627 2017-09-05

Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib

GastrointestinalHead & NeckThoracic

5 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Neoplasms, Colorectal Neoplasms

NCT01938456 2014-07-28

Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer

Phase 1 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT01362296 2014-07-11

An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer

Phase 2 Completed

134 enrolled 22 charts